Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)

References

• Li SY, Strelow A, Fontana EJ, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Nat Acad Sci USA. 2002;99(8):5567–5572.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2004;5(461):1–8.
   Google Scholar
• Suzuki N, Suzuki S, Duncan GS, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature. 2002;416(6882):750–754.
   PubMed Web of Science ®Google Scholar
• Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299(5615):2076–2079.
   PubMed Web of Science ®Google Scholar
• Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharamacol. 2010;80(12):1981–1991.
   PubMed Web of Science ®Google Scholar
• O’Neill LAJ. The interleukin-1 receptor/toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10–18.
   PubMed Web of Science ®Google Scholar
• Motshwene PG, Moncrieffe MC, Grossmann JG, et al. An oligomeric signaling platform formed by the toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem. 2009;284(37):25404–25411.
   PubMed Web of Science ®Google Scholar
• Lin SC, Lo YC, Wu H. Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465(7300):885–890.
   PubMed Web of Science ®Google Scholar
• Kollewe C, Mackensen AC, Neumann D, et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem. 2004;279(7):5227–5236.
   PubMed Web of Science ®Google Scholar
• Cao Z, Xiong J, Takeuchi M, et al. TRAF6 is a signal transducer for interleukin-1. Nature. 1996;383(6599):443–446.
   PubMed Web of Science ®Google Scholar
• Qian Y, Commane M, Ninomiya-Tsuji J, et al. IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B. J Biol Chem. 2001;276(45):41661–41667.
   PubMed Web of Science ®Google Scholar
• O’Neill LAJ, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol. 1998;63(6):650–657.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
   PubMed Web of Science ®Google Scholar
• Lye E, Mirtsos C, Suzuki N, et al. The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J Biol Chem. 2004;279(39):40653–40658.
   PubMed Web of Science ®Google Scholar
• Vollmer S, Strickson S, Zhang T, et al. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists. Biochem J. 2017;474(12):2027–2038.
   PubMedGoogle Scholar
• De Nardo D, Balka KR, Cardona Gloria Y, et al. Interleukin-1 receptor–associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. J Biol Chem. 2018;293(39):15195–15207.
   PubMed Web of Science ®Google Scholar
• Kim TW, Staschke K, Bulek K, et al. A critical role for IRAK4 kinase activity in Toll-like receptor–mediated innate immunity. J Exp Med. 2004;204(5):1025–1036.
   Google Scholar
• Lye E, Dhanji S, Calzascia T, et al. IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive immune responses. Eur J Immunol. 2008;38(3):870–876.
   PubMed Web of Science ®Google Scholar
• Koziczak-Holbro M, Littlewood-Evans A, Pöllinger B, et al. The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation. Arthritis Rheum. 2009;60(6):1661–1671.
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–2506.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Hoozemans JJM, van Haastert ES, Mulder SD, et al. Increased IRAK-4 kinase activity in Alzheimer’s disease; IRAK-1/4 inhibitor I prevents pro-inflammatory cytokine secretion but not the uptake of amyloid beta by primary human glia. J Clin Cell Immunol. 2014;5:4.
   Google Scholar
• Leaf IA, Nakagawa S, Johnson BG, et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J Clin Invest. 2017;127(1):321–334.
   PubMed Web of Science ®Google Scholar
• Genung NE, Guckian KM. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (IRAK4). Prog Med Chem. 2017;56:117–163.
   PubMedGoogle Scholar
• Chaudhary D, Robinson S, Romero DL. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptorassociated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015;58(1):96–110.
   PubMed Web of Science ®Google Scholar
• Information on NCT02996500. [cited 2018 Dec 13]. Available from: clinicaltrials.gov
   Google Scholar
• Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012–2015). Expert Opin Ther Pat. 2016;26(8):917932.
   Web of Science ®Google Scholar
• Aurigene Discovery Technologies Limited. Bicyclic heterocycles as inhibitors as IRAK4 inhibitors. WO2013042137A1.
   Google Scholar
• Aurigene Discovery Technologies Limited. Indazole and azaindazole compounds as IRAK-4 inhibitors. WO2017009798A1.
   Google Scholar
• Aurigene Discovery Technologies Limited. Substituted aza compounds as IRAK4 inhibitors. WO201700806.
   Google Scholar
• Aurigene Discovery Technologies Limited. Compounds and compositions for treating hematological disorders. WO2018178947A2.
   Google Scholar
• Curis press release. [updated 2018 Dec 2; cited 2018 Dec 13]. Available from: http://investors.curis.com/192018-01-17-Curis-Announces-Initiation-of-Phase-1-Trial-of-CA-4948-a-Small-Molecule-Inhibitor-of-IRAK4-Kinase-in-Patients-with-Lymphoma
   Google Scholar
• Information on NCT03328078. [cited 2018 Dec 13]. Available from: clinicaltrials.gov
   Google Scholar
• Bayer Pharma. Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments. WO2015091426A1.
   Google Scholar
• Bayer Pharma. New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs. WO2016083433A1.
   Google Scholar
• Bayer Pharma. Use of 2-substituted indazoles and prophylaxis of autoimmune diseases. WO2017207386A1.
   Google Scholar
• Bayer Pharma. Combinations of inhibitors of IRAK4 with inhibitors of BTK. WO2016174183A1.
   Google Scholar
• Bayer Pharma. Combinations of copanlisib. WO2017157792A1.
   Google Scholar
• Bayer Pharma. Novel substituted indazoles, methods for producing the same, pharmaceutical preparations that contain same, and use of same to produce drugs. WO2017108744A1.
   Google Scholar
• Bayer Pharma. Substituted 3-methylindazoles, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments. WO2017207385A1.
   Google Scholar
• Bayer Pharma. New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs. WO2017148902A1.
   Google Scholar
• Bayer Pharma. Substituted benzimidazoles, pharmaceutical preparations containing same, and use of same to produce drugs. WO2018060174A1.
   Google Scholar
• Bayer Pharma. Novel substituted benzimidazole, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments. WO2017207340A1.
   Google Scholar
• Bayer Pharma. New substituted benzimidazoles, methods for the production of same, pharmaceutical preparations containing same, and use of same to produce drugs. WO2018060072A1.
   Google Scholar
• Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof. WO2017024589A1.
   Google Scholar
• Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof. WO2017025064A1.
   Google Scholar
• Biogen MA Inc. Arenoazoles as IRAK4 inhibiting agents and their preparation. WO2016011390A1.
   Google Scholar
• Biogen MA Inc. IRAK4 Inhibiting agents. WO2017127430.
   Google Scholar
• Bristol-Myers Squibb Company. Heteroaryl substituted aminopyridine compounds. WO2016210034A1.
   Google Scholar
• Bristol-Myers Squibb Company. Heteroaryl substituted aminopyridine compounds. WO2016210036A1.
   Google Scholar
• Bristol-Myers Squibb Company. Heteroaryl substituted aminopyridine compounds. WO2016210037A1.
   Google Scholar
• Dudhgaonkar S, Ranade S, Nagar J, et al. Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity. J Immunol. 2017;198(3):1308–1319.
   PubMed Web of Science ®Google Scholar
• Bryan MC, Rajapaksa NS. Kinase inhibitors for the treatment of immunological disorders: recent advances. J Med Chem. 2018;61(20):9030–9058.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Thienopyridines and benzopthiophenes useful as IRAK4 inhibitors. WO2018209012A1.
   Google Scholar
• Galapogos NV. 6-[5-Amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK4 inhibitors. WO2017067848.
   Google Scholar
• Galapogos NV. Anti-inflammatory compositions comprising IRAK4 and JAK inhibitors. WO2018149925A1.
   Google Scholar
• Genentech, Inc. Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators. WO2017108723A2.
   Google Scholar
• Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods. WO2010051549A1.
   Google Scholar
• Genentech, Inc. Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators. WO2018083085.
   Google Scholar
• Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives. WO20181523681A1.
   Google Scholar
• Merck patent GMDH. Pyrimidine pyrazolyl derivatives and their use as IRAK inhibitors. WO2015106058A1.
   Google Scholar
• Merck patent GMDH. Heteroaryl compounds as IRAK inhibitors and uses thereof. WO2016081679A1.
   Google Scholar
• Ares Trading SA. Pyrimidine pyrazolyl derivatives. WO2014008992A1.
   Google Scholar
• Merck patent GMDH. Heteroaryl compounds as IRAK inhibitors and uses thereof. WO2017049068A1.
   Google Scholar
• Merck patent GMDH. Heteroaryl compounds as IRAK inhibitors and uses thereof. WO2017049069A1.
   Google Scholar
• Merck patent GMDH. Pyridazinone macrocyles as IRAK inhibitors and uses thereof. WO2016127024A1.
   Google Scholar
• Merck Patent GmbH. Macrocyclic pyridazinone derivatives. WO2014121942A1.
   Google Scholar
• MSD. Carboxamide inhibitors of IRAK4 activity. WO2016144844A1.
   Google Scholar
• MSD. Pyrazolopyrimidine inhibitors of IRAK4 activity. WO2016144846A1.
   Google Scholar
• MSD. Pyrazolopyridazine inhibitors of IRAK4 activity. WO2016144847A1.
   Google Scholar
• MSD. Pyrrolotriazine inhibitors of IRAK4 activity. WO2016144848A1.
   Google Scholar
• MSD. Thienopyrazine inhibitors of IRAK4 activity. WO2016144849A1.
   Google Scholar
• Lim J, Altman MD, Baker J, et al. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine3-carboxamide inhibitors of IRAK4. ACS Med Chem Lett. 2015;6(6):683–688.
   PubMed Web of Science ®Google Scholar
• MSD. Inhibitors of IRAK4 activity. WO2016053769A1.
   Google Scholar
• MSD. Inhibitors of IRAK4 activity. WO2016053770A1.
   Google Scholar
• MSD. Inhibitors of IRAK4 activity. WO2016053771A1.
   Google Scholar
• MSD. Inhibitors of IRAK4 activity. WO2016053772A1.
   Google Scholar
• Smith GF, Altman MD, Andresen B, et al. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorg Med Chem Lett. 2017;27(12):2721–2726.
   PubMed Web of Science ®Google Scholar
• Nimbus press release. [cited 2018 Dec 13]. Available from: http://www.nimbustx.com/192015/10/20/nimbus-therapeutics-announces-global-license-agreement-with-genentech/
   Google Scholar
• Nimbus Iris, Inc. IRAK inhibitors and uses thereof. WO2017004133A1.
   Google Scholar
• Nimbus Iris, Inc. IRAK inhibitors and uses thereof. WO2017004134A1.
   Google Scholar
• Nimbus Iris, Inc. Preparation of thiazolo[5,4-d]pyrimidine derivatives as IRAK kinase inhibitors and uses thereof. WO2015048281A1.
   Google Scholar
• Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 inhibitors and their preparation. WO2015150995A1.
   Google Scholar
• Lee KL, Ambler CM, Anderson DR, et al. Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design. J Med Chem. 2017;60(13):5521–5542.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators. WO2017033093.
   Google Scholar
• Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds. WO2017025849.
   Google Scholar
• AbbVie press release. [cited 2018 Dec 13]. Available from: https://news.abbvie.com/news/abbvie-completes-acquisition-pharmacyclics.htm
   Google Scholar
• Pharmacyclics LLC. Inhibitors of Interleukin-1 receptor-associated kinase. WO2017205762A1.
   Google Scholar
• Pharmacyclics LLC. Inhibitors of Interleukin-1 receptor-associated kinase. WO2017205766A1.
   Google Scholar
• Pharmacyclics LLC. Inhibitors of Interleukin-1 receptor-associated kinase. WO2017205769A1.
   Google Scholar
• Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds. WO2016172560A1.
   Google Scholar
• Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as IRAK inhibitors. WO2018081294A1.
   Google Scholar
• Rigel Pharmaceuticals, Inc. Benzoxazole compounds and methods for making and using the compounds. WO2017023941A1.
   Google Scholar
• Rigel Pharmaceuticals, Inc. 2,4-Diamino-pyrimidine compounds and method for making and using the compounds. WO2018005356A1.
   Google Scholar
• Rigel press release. [cited 2018 Dec 3]. Available from: https://www.rigel.com/index.php/pipeline/irak/
   Google Scholar
• Takeda Pharmaceutical Company Limited. Heterocyclic compound. WO2018052058A1.
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Preparation of pyrazole compounds as IRAK-4 inhibitors for the treatment autoimmune disorders and other diseases. WO2015068856A1.
   Google Scholar
• Cushing L, Stochaj W, Siegel M, et al. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptorassociated kinase 4 and controls cytokine induction in a cell type specific manner. J Biol Chem. 2014;289(15):10865–10875.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptorassociated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212(13):2189–2201.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia. 2007;21(1):37–43.
   PubMed Web of Science ®Google Scholar
• Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2(9):823–830.
   PubMed Web of Science ®Google Scholar